- Home
- KZIA
as 04-02-2025 4:00pm EST
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
| Founded: | 1994 | Country: | Australia |
| Employees: | N/A | City: | NEW SOUTH WALES 2113 |
| Market Cap: | 6.0M | IPO Year: | 1999 |
| Target Price: | $11.50 | AVG Volume (30 days): | 334.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.76 - $15.80 | Next Earning Date: | 04-11-2025 |
| Revenue: | $1,655,324 | Revenue Growth: | 248000.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kazia Therapeutics Limited News
KZIA Breaking Stock News: Dive into KZIA Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
PR Newswire
a month ago
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease
Insider Monkey
2 months ago
Is Kazia Therapeutics (KZIA) One of the Best ASX Stocks to Buy According to Hedge Funds?
MT Newswires
2 months ago
Sector Update: Health Care Stocks Gain Thursday
MT Newswires
2 months ago
Kazia Therapeutics Shares Rise After Breast Cancer Treatment Trial Announced
PR Newswire
2 months ago
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
Insider Monkey
2 months ago
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now?
PR Newswire
3 months ago
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
Compare KZIA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KZIA Kazia Therapeutics Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.